Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Neoplasms, Breast

In brief

The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer. The treatment will be given before surgery in combination with standard therapy.

Key facts

Study ID

NCT01220128

Run by

GlaxoSmithKline

People needed

66

Starts

2011-04-11

Expected to finish

2014-11-14

Last updated by the study team

2021-05-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient is ≥ 18 years of age at the time the informed consent to screening has been obtained.
• The patient has proven T1 with lymph node involvement or T2-T4c, any N, M0 primary invasive breast cancer, histologically confirmed by core needle biopsy.
• Isolated supraclavicular lymph node involvement is allowed.
• The patient's tumor shows WT1 antigen expression.
• The patient has one of the following histologically confirmed breast cancer subtypes:
• Estrogen receptor and/or progesterone positive tumor.
• Human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.
• HER2-negative breast cancer.
• Eastern Cooperative Oncology Group (performance status of 0 or 1 at the time of study treatment allocation.
• Baseline left ventricular ejection fraction of ≥ 50% as measured within six weeks prior to study treatment allocation by echocardiography or multi-gated acquisition(MUGA)scan.
• The patient shows normal organ function according to the following parameters(as measured within six weeks prior to treatment allocation)::
• Hemoglobin: Within normal range according to institutional standards.
• Absolute leukocyte count: Within normal range according to institutional standards.
• Absolute lymphocyte count: Within normal range according to institutional standards.
• Platelet count: Within normal range according to institutional standards
• Alanine aminotransferase: ≤ 2.5 x Upper Limit of Normal (ULN)
• Aspartate aminotransferase: ≤ 2.5 x ULN
• Total bilirubin: ≤ 1.5 x ULN. In the case of known Gilbert's syndrome ≤ 2 x ULN
• Serum creatinine: 1.5 x ULN
• Calculated creatinine clearance: > 50 mL/min
• A female patient of childbearing potential may be enrolled in the study, if the patient:
• has practiced adequate contraception for 30 days prior to study product administration, and
• has a negative pregnancy test within one week prior to treatment allocation and
• has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the study product administration series.In view of the investigator, the patient can and will comply with the requirements of the protocol.
• Written informed consent has been obtained from the patient prior to performance of any study specific procedure.

You may not qualify if…

• The patient has inflammatory breast cancer, which is defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion.
• Diagnosis established by incisional biopsy.
• Prior and concomitant neoadjuvant anti-breast-cancer treatments such as chemotherapy, immunotherapy / biological response modifiers, endocrine therapy, and radiotherapy, unless authorized specifically by the protocol.
• The patient is known to be human immunodeficiency virus -positive.
• The patient has symptomatic autoimmune disease such as, but not limited to multiple sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not excluded.
• The patient is known to have difficult-to-control hypertension, coronary artery disease, arrhythmia requiring treatment, clinically significant valvular disease, cardiomegaly on chest X-ray, ventricular hypertrophy on electrocardiogram or previous myocardial infarction or congestive heart failure.
• The patient has a history of allergic reactions likely to be exacerbated by any component of the investigational product used in the study.
• The patient has other concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.
• The patient has (or has had) previous or concomitant malignancies at other sites, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.
• The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent or to comply with the study procedures.
• The patient has received any investigational or non-registered product within 30 days preceding the first dose of study products or planned use during the study period.
• The patient requires concomitant treatment with any immunosuppressive agents or with systemic corticosteroids prescribed for chronic treatment.
• The patient has a significant disorder of coagulation or receives treatment with warfarin derivatives or heparin. Patients receiving individual doses of low molecular weight heparin outside of 24 hours prior to WT1-A10 + AS15 ASCI/placebo administration are eligible. Patients receiving prophylactic antiplatelet medications e.g. low-dose aspirin, and without a clinically-apparent bleeding tendency are eligible.

Where it is running

• GSK Investigational Site — Newark, Delaware, United States
• GSK Investigational Site — Plantation, Florida, United States
• GSK Investigational Site — Boston, Massachusetts, United States
• GSK Investigational Site — Ann Arbor, Michigan, United States
• GSK Investigational Site — Bend, Oregon, United States
• GSK Investigational Site — Memphis, Tennessee, United States
• GSK Investigational Site — Amarillo, Texas, United States
• GSK Investigational Site — Spokane, Washington, United States
• GSK Investigational Site — Brussels, Belgium
• GSK Investigational Site — Leuven, Belgium
• GSK Investigational Site — Namur, Belgium
• GSK Investigational Site — Lyon, France
• GSK Investigational Site — Saint-Herblain, France
• GSK Investigational Site — Tübingen, Baden-Wurttemberg, Germany
• GSK Investigational Site — Erlangen, Bavaria, Germany
• GSK Investigational Site — Frankfurt am Main, Hesse, Germany
• GSK Investigational Site — Rostock, Mecklenburg-Vorpommern, Germany
• GSK Investigational Site — Dortmund, North Rhine-Westphalia, Germany
• GSK Investigational Site — Essen, North Rhine-Westphalia, Germany
• GSK Investigational Site — Chemnitz, Saxony, Germany
• GSK Investigational Site — Kiel, Schleswig-Holstein, Germany
• GSK Investigational Site — Naples, Campania, Italy
• GSK Investigational Site — Aviano (PN), Friuli Venezia Giulia, Italy
• GSK Investigational Site — Genoa, Liguria, Italy
• GSK Investigational Site — Milan, Lombardy, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.